Why the study?
Athletes with myocarditis, pericarditis, valvular heart disease, and other acquired cardiovascular conditions require careful evaluation, disease-specific risk stratification, and shared decision-making when considering competitive sports participation.
Answers are grounded in this paper and cite their sources.
Provides the AHA/ACC expert consensus and clinical considerations for return-to-play eligibility in competitive athletes with myocarditis, pericarditis, valvular heart disease, and other acquired cardiovascular conditions.
Athletes with myocarditis, pericarditis, valvular heart disease, and other acquired cardiovascular conditions require careful evaluation when considering competitive sports participation. This document outlines key clinical considerations, risk factors, and expert consensus, serving as the rationale for Section V of the recent AHA/ACC Scientific Statement: Clinical Considerations for Competitive Sports Participation for Athletes with Cardiovascular Abnormalities. Disease-specific risk stratification and shared decision-making are essential in determining return-to-play eligibility. This Task Force document addresses myocarditis, pericarditis, the cardiovascular impact of respiratory viral infections, incidental myocardial fibrosis, Kawasaki disease, infiltrative cardiomyopathies, and valvular heart disease.
No takes yet. Share an insight, caveat, or question.
Guseh et al. (2026) studied Myocarditis, pericarditis, valvular heart disease, and other acquired cardiovascular conditions in athletes. Disease-specific risk stratification and shared decision-making guide return-to-play eligibility for athletes with myocarditis, pericarditis, and valvular heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: